CriticalSecond-generation systemic triazole antifungal×Triazole derivatives, systemic antifungals
Updated · Methodology
Mechanism
Voriconazole is a strong inhibitor of the enzyme CYP3A4 (voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA, and voriconazole label, US Food and Drug Administration, FDA), and isavuconazole is a sensitive substrate of this enzyme (isavuconazole label, FDA). The two drugs have not been studied together, and the documents give no figures for this pair. Ketoconazole, another strong CYP3A4 inhibitor, increased isavuconazole exposure (area under the curve, AUC) by 422%, and lopinavir with ritonavir by 96% (isavuconazole SmPC, EMA). In the other direction, isavuconazole is a moderate CYP3A4 inhibitor and may raise levels of drugs that this enzyme metabolises (isavuconazole SmPC and label, EMA and FDA). CYP2C19, CYP2C9 and CYP3A4 metabolise voriconazole, and inhibitors of these enzymes may raise its levels (voriconazole SmPC and label, EMA and FDA), but there are no measurements for this direction either.
Symptoms
Higher isavuconazole levels may bring more adverse reactions (isavuconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). At three times the usual maintenance dose, headache, dizziness, tingling, numbness in the mouth, sleepiness, poor attention, taste disturbance, dry mouth, diarrhoea, vomiting, flushing, anxiety, restlessness, palpitations, fast heart rate, sensitivity to light and joint pain were more frequent (isavuconazole SmPC, EMA, and isavuconazole label, US Food and Drug Administration, FDA). Both drugs can cause liver injury, including hepatitis and liver failure (voriconazole SmPC, EMA, and isavuconazole label, FDA). QT prolongation has been reported with voriconazole, while isavuconazole shortens the QT interval, more so at higher concentrations (voriconazole and isavuconazole SmPCs, EMA). The documents do not say how these effects combine.
Management
The US isavuconazole label contraindicates the combination: it contraindicates all strong CYP3A4 inhibitors. According to its own documents, voriconazole is a strong CYP3A4 inhibitor (isavuconazole and voriconazole labels, US Food and Drug Administration, FDA, and voriconazole summary of product characteristics, SmPC, European Medicines Agency, EMA). The European isavuconazole SmPC is less strict and does not name voriconazole: among strong CYP3A4 inhibitors it contraindicates only ketoconazole. With the others, the SmPC keeps the isavuconazole dose unchanged but advises caution, because adverse reactions may increase (isavuconazole SmPC, EMA). No document gives a waiting time between stopping one drug and starting the other. The mean half-life of isavuconazole is 130 hours (FDA), while the half-life of voriconazole depends on the dose and cannot be used to predict its accumulation or elimination (voriconazole SmPC, EMA). Monitor liver function during treatment with either drug. With voriconazole, measure transaminases and bilirubin at the start and at least weekly during the first month (voriconazole label, FDA). With isavuconazole, evaluate liver tests at the start and during treatment (isavuconazole label, FDA). Stop isavuconazole if signs of liver disease develop that may be due to it (FDA), and stop voriconazole if liver tests rise markedly, unless the benefit-risk assessment justifies continuing (voriconazole SmPC and label, EMA and FDA). If the patient has had an allergy to one azole antifungal, prescribe the other with caution (isavuconazole and voriconazole SmPCs, EMA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- FDA: Vfend (voriconazole) prescribing information – CYP3A4 inhibitor, statin/immunosuppressant interactions (2020)– FDA Vfend label, Drug Interactions §7 – tacrolimus, cyclosporine, sirolimus, statins; DailyMed setid ce3ef5cf-3087-4d92-9d94-9eb8287228db
- EMA: Ficha técnica: Voriconazol (EU/1/02/212), sección 4.5 (2026)– EMA SmPC vía AEMPS CIMA, nº 02212015 (EU/1/02/212), secciones 4.2, 4.4 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Isavuconazol (EU/1/15/1036), sección 4.5 (2026)– EMA, Cresemba 100 mg cápsulas duras (Basilea Pharmaceutica Deutschland, autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 1151036002, consultada 24.10.2026, sin fecha de revisión en CIMA, secciones 4.3, 4.4, 4.5, 4.9 y 5.2
- FDA: CRESEMBA (isavuconazonium sulfate) prescribing information (2025)– FDA, DailyMed setid 8f7f73b8-586a-4df0-935f-fecd4696c16c (Astellas Pharma US), revisión 04/2025 (versión 21), secciones 4, 5.1, 5.5, 7, 10 y 12.3